{"nctId":"NCT01419197","briefTitle":"A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy","startDateStruct":{"date":"2011-09"},"conditions":["Breast Cancer"],"count":602,"armGroups":[{"label":"Trastuzumab emtansine","type":"EXPERIMENTAL","interventionNames":["Drug: Trastuzumab emtansine"]},{"label":"Treatment of physician's choice","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Treatment of physician's choice"]}],"interventions":[{"name":"Trastuzumab emtansine","otherNames":["Kadcyla","T-DM1"]},{"name":"Treatment of physician's choice","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult participants ≥ 18 years of age.\n* Histologically or cytologically documented breast cancer.\n* Metastatic or unresectable locally advanced/recurrent breast cancer.\n* HER2-positive disease by prospective laboratory confirmation.\n* Disease progression on the last regimen received as defined by the investigator.\n* Prior treatment with an trastuzumab, a taxane, and lapatinib.\n* Disease progression after at least two regimens of HER2-directed therapy in the metastatic or unresectable locally advanced/recurrent setting.\n* Adequate organ function, as evidenced by laboratory results.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n* Left ventricular ejection fraction (LVEF) ≥ 50% by echocardiogram or multi gated acquisition scan.\n\nExclusion Criteria:\n\n* Chemotherapy ≤ 21 days before first study treatment.\n* Trastuzumab ≤ 21 days before first study treatment.\n* Lapatinib ≤ 14 days before first study treatment.\n* Prior enrollment in a trastuzumab emtansine containing study, regardless whether the patient received prior trastuzumab emtansine.\n* Brain metastases that are untreated or symptomatic, or require any radiation, surgery or corticosteroid therapy to control symptoms within 1 month of randomization.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival","description":"Progression-free survival was defined as the time from randomization to the first documented disease progression by investigator assessment using Response Evaluation Criteria In Solid Tumors (RECIST) v1.1 or death from any cause, whichever occurred first. Progression-free survival was a co-primary endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"3.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Overall Survival","description":"Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was a co-primary endpoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"14.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Objective Response","description":"An objective response was defined as a complete or partial response determined on 2 consecutive occasions ≥ 4 weeks apart using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete response was defined as the disappearance of all target and non-target lesions. Any pathological lymph nodes (whether target or non-target) must be \\< 10 mm on the short axis. Partial response was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum. Participants who had no post-baseline tumor assessment were counted as non-responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"8.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of the Objective Response","description":"Duration of the objective response was defined as the time from the first tumor assessment that was judged to indicate that the patient had an objective response to the time of first documented disease progression using RECIST v1.1 per investigator assessment or death from any cause, whichever occurred first.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":null},{"groupId":"OG001","value":"NA","spread":null}]}]}]},{"type":"SECONDARY","title":"6-month and 1-year Survival","description":"6-month and 1-year survival were defined as the percentage of participants who were alive at 6 months and 1 year, respectively, as estimated using Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":null},{"groupId":"OG001","value":"78.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"56.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Pain Symptom Progression","description":"Time to pain symptom progression was defined as the time from randomization to the first documentation of an increase in narcotic use and/or a 10 point increase from Baseline in the pain score as measured by the European Organisation for Research and Treatment of Cancer, Quality of Life Questionnaire for patients with bone metastases (EORTC QLQ-BM22). The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"3.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the EORTC QLQ-BM22 Pain Score on Day 1 of Each Cycle","description":"The EORTC QLQ-BM22 assesses the symptoms of bone metastases using 22 items: 5 items for sites of pain, 3 pain characteristics, 8 functional interference aspects, and 6 psychosocial aspects. The pain score was derived from the 3 pain characteristic items. Each item was rated on a 4-point scale, where 1=Not at all to 4=Very much. The pain score was the sum of the 3 pain characteristic scores and was normalized to a scale of 0 to 100. A higher score indicates greater pain. A negative change score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.4","spread":"21.1"},{"groupId":"OG001","value":"-9.4","spread":"22.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"21.1"},{"groupId":"OG001","value":"-6.1","spread":"21.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"19.6"},{"groupId":"OG001","value":"-3.8","spread":"24.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.6","spread":"22.8"},{"groupId":"OG001","value":"-2.7","spread":"18.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"23.5"},{"groupId":"OG001","value":"2.4","spread":"17.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"23.8"},{"groupId":"OG001","value":"-1.5","spread":"15.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"21.0"},{"groupId":"OG001","value":"2.2","spread":"18.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.8","spread":"22.2"},{"groupId":"OG001","value":"6.7","spread":"20.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.9","spread":"21.2"},{"groupId":"OG001","value":"1.6","spread":"11.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.5","spread":"23.1"},{"groupId":"OG001","value":"0.0","spread":"8.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.3","spread":"25.8"},{"groupId":"OG001","value":"1.6","spread":"7.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.0","spread":"23.3"},{"groupId":"OG001","value":"2.2","spread":"12.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.1","spread":"21.8"},{"groupId":"OG001","value":"0.0","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.2","spread":"22.0"},{"groupId":"OG001","value":"0.0","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.3","spread":"19.6"},{"groupId":"OG001","value":"-3.7","spread":"6.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"22.9"},{"groupId":"OG001","value":"-5.6","spread":"7.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"12.0"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"9.3"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.6","spread":"23.1"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.7","spread":"6.4"},{"groupId":"OG001","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"21.8"},{"groupId":"OG001","value":"-9.0","spread":"23.3"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (Final Analysis)","description":"Overall survival was defined as the time from randomization to death from any cause.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"15.8","spread":null}]}]}]},{"type":"SECONDARY","title":"6-month and 1-year Survival (Final Analysis)","description":"6-month and 1-year survival were defined as the percentage of participants who were alive at 6 months and 1 year, respectively, as estimated using Kaplan-Meier method.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91.3","spread":null},{"groupId":"OG001","value":"78.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"76.5","spread":null},{"groupId":"OG001","value":"65.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":102,"n":403},"commonTop":["Nausea","Fatigue","Headache","Constipation","Asthenia"]}}}